PortalPublikationenTreatment satisfaction of adult patients with moderate-to-se...

Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

Standard

Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey. / Augustin, Matthias; Nosbaum, Audrey; Werfel, Thomas; Grond, Susanne; Reed, Catherine; Lampropoulou, Anastasia; Tietz, Nicole; Irvine, Alan D; Riedl, Elisabeth.

in: J DERMATOL TREAT, Jahrgang 34, Nr. 1, 2276047, 12.2023.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Augustin, M, Nosbaum, A, Werfel, T, Grond, S, Reed, C, Lampropoulou, A, Tietz, N, Irvine, AD & Riedl, E 2023, 'Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey', J DERMATOL TREAT, Jg. 34, Nr. 1, 2276047. https://doi.org/10.1080/09546634.2023.2276047

APA

Augustin, M., Nosbaum, A., Werfel, T., Grond, S., Reed, C., Lampropoulou, A., Tietz, N., Irvine, A. D., & Riedl, E. (2023). Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey. J DERMATOL TREAT, 34(1), [2276047]. https://doi.org/10.1080/09546634.2023.2276047

Vancouver

Augustin M, Nosbaum A, Werfel T, Grond S, Reed C, Lampropoulou A et al. Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey. J DERMATOL TREAT. 2023 Dez;34(1). 2276047. https://doi.org/10.1080/09546634.2023.2276047

Bibtex

@article{7afa65c366354556ab3cc9a85b8206b8,
title = "Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey",
abstract = "INTRODUCTION: We explored patient satisfaction with baricitinib, an oral Janus kinase inhibitor, in patients with atopic dermatitis (AD) treated in routine clinical practice.METHODS: Adults with moderate-to-severe AD treated with baricitinib in clinical practice for ≥4 weeks in France, Germany, and the UK completed a one-time online survey under market research methodologies. Treatment satisfaction was assessed using a Likert scale and abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). Patients reported demographic, disease, and treatment information. Data were analyzed descriptively.RESULTS: The survey was completed by 170 patients with a mean age of 39.3 years (SD = 13.5), 59% (n = 101) were female. At baricitinib initiation, 79% rated their AD as {"}Severe{"}, yet 28% reported body surface area (BSA) involvement ≥10%. Most were {"}Satisfied{"} or {"}Very satisfied{"} (76%/18%) with baricitinib, with high rates reported for controlling itch (36%/56%). Itch improvements were noted by 97% of patients. Some tapered/stopped (50%/32%) topical corticosteroid use, aligned with reported improvements on the patient global assessment and BSA. Mean TSQM-9 convenience score was 78.0 (SD = 14.0).CONCLUSIONS: Satisfaction with itch control was particularly high, reflected in rates of improvement in itch since starting baricitinib. On the TSQM-9, the convenience score was the highest. Many patients tapered/stopped concomitant topicals, indicating baricitinib's effect in controlling AD symptoms.",
keywords = "Humans, Adult, Female, Male, Patient Satisfaction, Dermatitis, Atopic/drug therapy, Cross-Sectional Studies, Pruritus, France, Germany, United Kingdom, Severity of Illness Index, Treatment Outcome, Double-Blind Method",
author = "Matthias Augustin and Audrey Nosbaum and Thomas Werfel and Susanne Grond and Catherine Reed and Anastasia Lampropoulou and Nicole Tietz and Irvine, {Alan D} and Elisabeth Riedl",
year = "2023",
month = dec,
doi = "10.1080/09546634.2023.2276047",
language = "English",
volume = "34",
journal = "J DERMATOL TREAT",
issn = "0954-6634",
publisher = "informa healthcare",
number = "1",

}

RIS

TY - JOUR

T1 - Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

AU - Augustin, Matthias

AU - Nosbaum, Audrey

AU - Werfel, Thomas

AU - Grond, Susanne

AU - Reed, Catherine

AU - Lampropoulou, Anastasia

AU - Tietz, Nicole

AU - Irvine, Alan D

AU - Riedl, Elisabeth

PY - 2023/12

Y1 - 2023/12

N2 - INTRODUCTION: We explored patient satisfaction with baricitinib, an oral Janus kinase inhibitor, in patients with atopic dermatitis (AD) treated in routine clinical practice.METHODS: Adults with moderate-to-severe AD treated with baricitinib in clinical practice for ≥4 weeks in France, Germany, and the UK completed a one-time online survey under market research methodologies. Treatment satisfaction was assessed using a Likert scale and abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). Patients reported demographic, disease, and treatment information. Data were analyzed descriptively.RESULTS: The survey was completed by 170 patients with a mean age of 39.3 years (SD = 13.5), 59% (n = 101) were female. At baricitinib initiation, 79% rated their AD as "Severe", yet 28% reported body surface area (BSA) involvement ≥10%. Most were "Satisfied" or "Very satisfied" (76%/18%) with baricitinib, with high rates reported for controlling itch (36%/56%). Itch improvements were noted by 97% of patients. Some tapered/stopped (50%/32%) topical corticosteroid use, aligned with reported improvements on the patient global assessment and BSA. Mean TSQM-9 convenience score was 78.0 (SD = 14.0).CONCLUSIONS: Satisfaction with itch control was particularly high, reflected in rates of improvement in itch since starting baricitinib. On the TSQM-9, the convenience score was the highest. Many patients tapered/stopped concomitant topicals, indicating baricitinib's effect in controlling AD symptoms.

AB - INTRODUCTION: We explored patient satisfaction with baricitinib, an oral Janus kinase inhibitor, in patients with atopic dermatitis (AD) treated in routine clinical practice.METHODS: Adults with moderate-to-severe AD treated with baricitinib in clinical practice for ≥4 weeks in France, Germany, and the UK completed a one-time online survey under market research methodologies. Treatment satisfaction was assessed using a Likert scale and abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). Patients reported demographic, disease, and treatment information. Data were analyzed descriptively.RESULTS: The survey was completed by 170 patients with a mean age of 39.3 years (SD = 13.5), 59% (n = 101) were female. At baricitinib initiation, 79% rated their AD as "Severe", yet 28% reported body surface area (BSA) involvement ≥10%. Most were "Satisfied" or "Very satisfied" (76%/18%) with baricitinib, with high rates reported for controlling itch (36%/56%). Itch improvements were noted by 97% of patients. Some tapered/stopped (50%/32%) topical corticosteroid use, aligned with reported improvements on the patient global assessment and BSA. Mean TSQM-9 convenience score was 78.0 (SD = 14.0).CONCLUSIONS: Satisfaction with itch control was particularly high, reflected in rates of improvement in itch since starting baricitinib. On the TSQM-9, the convenience score was the highest. Many patients tapered/stopped concomitant topicals, indicating baricitinib's effect in controlling AD symptoms.

KW - Humans

KW - Adult

KW - Female

KW - Male

KW - Patient Satisfaction

KW - Dermatitis, Atopic/drug therapy

KW - Cross-Sectional Studies

KW - Pruritus

KW - France

KW - Germany

KW - United Kingdom

KW - Severity of Illness Index

KW - Treatment Outcome

KW - Double-Blind Method

U2 - 10.1080/09546634.2023.2276047

DO - 10.1080/09546634.2023.2276047

M3 - SCORING: Journal article

C2 - 37965779

VL - 34

JO - J DERMATOL TREAT

JF - J DERMATOL TREAT

SN - 0954-6634

IS - 1

M1 - 2276047

ER -